GlassScriptPhysician profile
David Bj Babitt
NPI 1417447228
$2,934.80
in general payments reported to CMS, 2019-2025
27 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2021: $89.31 · 2022: $19.17 · 2023: $417 · 2024: $1,097 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $313.84 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Eisai INC. | $296.97 | 2023-2025 | |
| Abbvie INC. | $296.40 | 2023-2025 | Botox |
| Novartis Pharmaceuticals Corporation | $276.89 | 2024-2025 | |
| Pfizer INC. | $264.42 | 2023-2025 | |
| Ucb, INC. | $243.66 | 2023-2025 | Fintepla, Rystiggo |
| Acadia Pharmaceuticals INC | $159.52 | 2024-2025 | Nuplazid |
| Akcea Therapeutics, INC. | $146.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Neurocrine Biosciences, INC. | $105.68 | 2023-2025 | Ingrezza |
| Springworks Therapeutics, INC. | $103.23 | 2025 | Gomekli |
| Alexion Pharmaceuticals, INC. | $74.09 | 2021 | |
| Biogen, INC. | $69.51 | 2021-2025 | Skyclarys, Vumerity, Tysabri |
| Otsuka America Pharmaceutical, INC. | $65.61 | 2023-2024 | Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $65.41 | 2023-2025 | Hyqvia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $43.35 | 2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Vanda Pharmaceuticals INC. | $42.18 | 2024 | Ponvory |
| Catalyst Pharmaceuticals, INC. | $41.82 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $30.39 | 2024 | Dysport |
| Emd Serono, INC. | $24.54 | 2024 | |
| Averitas Pharma INC. | $24.13 | 2024 | Qutenza |
| Lilly USA, LLC | $23.78 | 2024 | Emgality |
| C2n Diagnostics, LLC | $23.02 | 2025 | Precivityad2 |
| Genzyme Corporation | $19.79 | 2023 | |
| Csl Behring | $19.53 | 2023 | Hizentra |
| Xeris Pharmaceuticals, INC. | $19.17 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.65 | 2024 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Babitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.